Holen Sie sich die Stockscreener-App
18.23
1.00%
0.18
Handel nachbörslich:
18.54
0.31
+1.70%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics at Canaccord Genuity: Strategic Insights from Growth Conference - Investing.com Canada
Travere Therapeutics Receives Positive Growth Outlook from Analysts Amid Filspari's Promising Market Potential and Strategic Initiatives - AInvest
Travere Therapeutics Approves Inducement Equity Grants for New Employees - AInvest
Trendlines Converge — Decision Point for Travere Therapeutics Inc.Earnings Performance Report & Entry Point Confirmation Alerts - beatles.ru
Ichimoku Cloud Indicates Uncertainty Around Travere Therapeutics Inc. [Weekly Risk Report]Free Verified Swing Trading Watchlist - 선데이타임즈
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2025 Earnings Call Transcript - MSN
Travere Therapeutics Sees Promising Growth with FILSPARI - AInvest
Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics (TVTX) Is Up 8.3% After Revenue Jump and Narrower Losses in Q2 – What's Changed - simplywall.st
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics price target raised to $34 from $32 at Citi - MSN
Travere Therapeutics Earnings Call Highlights FILSPARI Success - TipRanks
Healthcare Stocks Under the Spotlight: Eli Lilly & Co, Arrowhead Pharmaceuticals, and Travere Therapeutics - AInvest
Travere Therapeutics Reports Strong Q2 2025 Growth - MSN
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs - MSN
Travere Therapeutics price target raised to $32 from $30 at Wedbush - Yahoo Finance
Travere Therapeutics shares fall 5.16% intraday despite positive earnings report and price target increase. - AInvest
Scotiabank Raises Price Target for Travere Therapeutics (TVTX) t - GuruFocus
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Path To Profitability - simplywall.st
Travere Therapeutics price target raised to $31 from $30 at Scotiabank - TipRanks
Stifel lowers Travere Therapeutics stock price target to $20 on FSGS approval uncertainty - Investing.com
Stifel lowers Travere Therapeutics stock price target to $20 on FSGS approval uncertainty By Investing.com - Investing.com South Africa
Wedbush Lifts Price Target on Travere Therapeutics to $32 From $30, Keeps Outperform Rating - MarketScreener
TVTX: Wedbush Raises Price Target and Maintains Outperform Ratin - GuruFocus
Travere: Q2 Earnings Snapshot - Huron Daily Tribune
Travere signals accelerating FILSPARI growth and prepares for FSGS launch while advancing REMS modifications - MSN
Earnings call transcript: Travere Therapeutics Q2 2025 beats revenue forecasts - Investing.com Canada
Travere Therapeutics Reports Second Quarter 2025 Financial Results - BioSpace
Travere Therapeutics: Scaling the Rare Disease Ladder—Can FILSPARI Sustain Its Momentum? - AInvest
Contradictions Unveiled: Travere Therapeutics' 2025Q2 Earnings Call Highlights Regulatory Challenges and Market Dynamics - AInvest
Transcript : Travere Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Travere Therapeutics 2025 Q2 Earnings Strong Performance with 81.9% Net Loss Reduction - AInvest
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings - Yahoo Finance
Travere Therapeutics, Inc. SEC 10-Q Report - TradingView
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Travere Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Travere Therapeutics shares rise as Q2 results top expectations By Investing.com - Investing.com Australia
Travere Therapeutics shares rise as Q2 results top expectations - Investing.com India
Travere Therapeutics Inc Reports Q2 2025 Earnings: EPS Loss of $0.14 Beats Estimates, Revenue Surpasses Expectations at $114.4 Million - GuruFocus
Travere Therapeutics earnings beat by $0.16, revenue topped estimates - Investing.com Canada
Is Travere Therapeutics (NASDAQ:TVTX) Using Too Much Debt? - 富途牛牛
Travere Therapeutics to Participate at Upcoming Investor ConferencesAugust 5, 2025 - BioSpace
Earnings Preview: Travere Therapeutics - 富途牛牛
RBC to announce third quarter results on August 27, 2025 - The Globe and Mail
Travere Therapeutics Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Trend Dashboard Flags Travere Therapeutics Inc. As Potential Swing TradeExpert Verified Stock Trade Ideas Backed by Data - metal.it
What are the technical indicators suggesting about Travere Therapeutics Inc.Achieve triple-digit returns with smart investing - Jammu Links News
Should I hold or sell Travere Therapeutics Inc. stock in 2025Grow your portfolio with growth-oriented stocks - Jammu Links News
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):